-
Researchers to share weight loss results from bimagrumab and semaglutide combo
Steven B. Heymsfield, MD, Louis J. Aronne, MD, FACP, DABOM, and other panelists will explain insights into the treatment of obesity and overweight from BELIEVE.
-
Investigators to reveal full results from REDEFINE 1, 2 in Chicago
Melanie J. Davies, MB, ChB, MD, and other researchers will review data on combination therapy for weight loss using a fixed-dose combination of semaglutide and long-acting amylin analogue cagrilintide.
-
Symposium will explore next gen agents for type 2 diabetes and obesity
Panelists including Dimitris Papamargaritis, MCRP, PhD, will discuss emerging therapies targeting the hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin.
-
Speakers to stress importance of preparing for heart failure ‘tidal wave’
Adrian F. Hernandez, MD, MHS, and other experts will outline new developments in heart failure screening, prevention, and therapy related to diabetes.
-
Experts to explore using AI and diabetes tech to improve outcomes
Panelists including Mindy Lee, MD, PhD, and Yaa Kumah-Crystal, MD, MPH, will review recent advancements in medical technology and artificial intelligence and their potential clinical implications.
-
Debate to weigh benefits and drawbacks of OTC CGMs
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and David Ahn, MD, will assess the impact of non-prescription use of continuous glucose monitors.